Last Patient in Isotechnika Inc.'s Phase 2b Kidney Transplant Trial Completes Six Month Treatment

EDMONTON, Jan. 3 /CNW/ - Isotechnika Inc. (TSX:ISA) announced today that the last patient enrolled in the Company’s Phase 2b kidney transplant trial has completed the six month trial.

MORE ON THIS TOPIC